# An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

> **NCT02782845** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 53 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Immunochemotherapy
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT02782845
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2016-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782845, "An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02782845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*